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Aims High-density lipoproteins (HDLs) are circulating micelles that transport proteins, lipids, and miRNAs. HDL-
transported miRNAs (HDL-miRNAs) have lately received attention but their effects on vascular cells are not fully
understood. Additionally, whether cardiovascular risk factors affect HDL-miRNAs levels and miRNA transfer to re-
cipient cells remains equally poorly known. Here, we have investigated the changes induced by hypercholesterolae-




Pigs were kept on a high-fat diet (HC; n = 10) or a normocholesterolaemic chow (NC; n = 10) for 10 days reaching
cholesterol levels of 321.0 (229.7–378.5) mg/dL and 74.0 (62.5–80.2) mg/dL, respectively. HDL particles were iso-
lated, purified, and quantified. HDL-miRNA profiling (n = 149 miRNAs) of HC- and NC-HDLs was performed by
multipanel qPCR. Cell cultures of porcine aortic ECs were used to determine whether HDL-miRNAs were deliv-
ered to ECs. Potential target genes modulated by miRNAs were identified by bioinformatics and candidate miRNAs
were validated by molecular analysis. In vivo effects in the coronary arteries of normocholesterolaemic swine admin-
istered HC- or NC-HDLs were analysed. Among the HDL-miRNAs, four were found in different amounts in HC-
and NC-HDL (P < 0.05). miR-126-5p and -3p and miR-30b-5p (2.7, 1.7, and 1.3, respectively) were found in
higher levels and miR-103a-3p and miR-let-7g-5p (-1.6, -1.4, respectively) in lower levels in HC-HDL. miR-126-
5p and -3p were transferred from HC-HDL to EC (2.5; P < 0.05), but not from NC-HDL, by a SRB1-mediated
mechanism. Bioinformatics revealed that HIF1a was the miR-126 target gene with the highest predictive value,
which was accordingly found to be markedly reduced in HC-HDL-treated ECs and in miR126 mimic transfected
ECs. In vivo validation confirmed that HIF1a was diminished in the coronary endothelial layer of NC pigs adminis-
tered HC-HDL vs. those administered NC-HDL (P < 0.05).
....................................................................................................................................................................................................
Conclusion Hypercholesterolaemia induces changes in the miRNA content of HDL enhancing miR126 and its delivery to ECs
with the consequent down-regulation of its target gene HIF1a.
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1. Introduction
MicroRNAs (miRNAs) are short, non-coding RNAs (22 nucleotide in
length) that control gene expression through post-transcriptional regula-
tion of target mRNAs. Extracellular miRNAs have been detected in mul-
tiple lipid-based carriers including exosomes, microparticles, and
lipoproteins.1 Indeed, high-density lipoproteins (HDLs) are lipoproteins
that in addition to cholesterol, transport other lipid species, proteins,
and miRNAs.2 HDL particles exert multiple cardiovascular protective
functions. Under physiological conditions HDL-cargo molecules that
maintain cardiovascular homeostasis and function by promoting circulat-
ing cells, endothelial cells (ECs), vessel wall stabilization, and regulating
reverse cholesterol transport and ischaemia/reperfusion injury.3–5 In this
regard, HDL-mediated transport and delivery of miRNAs to recipient
cells can regulate expression of genes involved in lipid metabolism, in-
flammation, angiogenesis, and apoptosis.6–9
Robust epidemiological data supports that increasing HDL-choles-
terol (HDL-c) levels predict improved cardiovascular outcomes; how-
ever, HDL-c raising therapies in secondary prevention trials have failed
to demonstrate cardiovascular benefits.10 As such, within the last de-
cade, it has become increasingly evident that the measure of the choles-
terol levels transported by HDL (HDL-c) is not a good read-out of HDL
beneficial effects because the presence of excess cholesterol (hypercho-
lesterolaemia) increases the transport of cholesterol in detriment of
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.other beneficial cargos. Moreover, the presence of comorbidities modi-
fies HDL particle composition and function hampering HDL-beneficial
effects and even becoming deleterious.11–16 We have recently demon-
strated that HDL in vivo remodelling is affected by low-density
lipoprotein (LDL) cholesterol levels. Indeed, the presence of hypercho-
lesterolaemia influences HDL lipidomic and proteomic profile and ren-
ders HDL particles dysfunctional.17–19 Particularly, HDL particles
formed under hypercholesterolaemic conditions, as compared to HDL
particles formed in a normocholesterolaemic milieu, have lower levels of
phosphatidylcholine-lipid species and higher levels of cholesteryl esters
and a lower cargo of several proteins with known cardioprotective func-
tions including lipocalin retinol binding protein-4 and apolipoprotein-M.
Interestingly, we have further proved that such adverse structural
remodelling is associated with a marked reduction in HDL anti-oxidant
and cholesterol efflux capacity and complete loss of HDL-induced cardi-
oprotection.20 However, to date, there is no information on the impact
of hypercholesterolaemia on HDL-transported miRNA (HDL-miRNA)
content or on the possible effects of HDL-miRNAs on EC gene regula-
tion. Accordingly, in the present study, we aimed to investigate the
HDL-miRNA cargo of HDL formed in vivo in hypercholesterolaemic
conditions and whether the tentative modifications were able to differ-
entially regulate gene expression in target cells.
2. Methods
Experimental procedures were reviewed and approved by the
Institutional Animal Care and Use Committees (CEEA-IR) and autho-
rized by the Animal Experimental Committee of the local government
(#5601) in accordance to the Spanish law (RD 53/2013) and European
Directive 2010/63/EU. In addition, the investigation conforms to the
Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised 1985),
follows the ARRIVE guidelines and is committed to the 3Rs of laboratory
animal research and consequently used the minimal number of animals
to reach statistical significance.21 All animals were allowed to acclimate
7 days prior to any intervention and housed in individual cages under
light-controlled conditions and room temperature.
2.1 Experimental model of
hypercholesterolaemia and HDL isolation
2.1.1 Experimental animal model
Four-month-old pigs (N = 20; weight: 40kg) randomly received either
regular normocholesterolaemic chow (NC; n = 10) or a high-fat/high-
cholesterol diet (HC; n = 10) for 10 days (composition of the diet is de-
tailed in Supplementary material online, Table S1). HC animals developed
high LDL-cholesterol levels similar to those found in hypercholesterolae-
mic humans, 321.0 (229.7–378.5) mg/dL, while NC-animals had 74.0
(62.5–80.2) mg/dL (P < 0.0001; Supplementary material online, Table S2).22
2.1.2 HDL isolation and purification
On Day 10, animals were tranquilized by intramuscular injection of
Azoperone (40 mg/mL; 7 mg/kg), anaesthesia was induced by propofol
(2%; 3 mg/kg), and maintained by isofluorane inhalation (3%). Animals
were then sacrificed by propofol overdose and potassium chloride
(2 M). HDLs were isolated by standard sequential preparative ultracen-
trifugation techniques from plasma-EDTA (ethylenediaminetetra-acetic
acid) before sacrifice as previously reported.19 Protein levels in HDL
were quantified by standard Bradford protein assay (PierceTM BCA
Protein Assay Kit, Thermo Fisher Scientific, Waltham, Massachusetts,
USA). Lipoprotein cholesterol content was assessed by the Cholesterol
Quantification Kit (MAK043-Sigma-Aldrich; MO, USA). The purity of the
HDL fraction was confirmed by excluding the presence of ApoB (by-aga-
rose gel electrophoresis), microvesicles (FACS for Anexin Vþ microve-
sicles), and exosomes (western blots for transpanins CD63 and CD81;
exosomes isolated by ExoMirTM Kit).23
2.1.3 HDL miRNA isolation
HDL samples were thawed on ice and centrifuged at 3000 g for 5 min at
4C. An aliquot of 200lL per sample (protein concentration HC: 5.7mg/
mL and NC: 5.6mg/mL) was transferred to a FluidX tube and 60lL
of lysissolution buffer containing 1 lg carrier-RNA per 60 lL lysis
solution buffer and RNA spike-in template mixture were added to the
sample and mixed for 1 min and incubated for 7 min at room tempera-
ture, followed by addition of 20lL protein precipitation solution buffer.
Total RNA was extracted from the samples using miRCURY RNA isola-
tion Kit through a high throughput bead-based protocol v.1 (Exiqon,
Vedbaek, Denmark) in an automated 96-well format. The purified total
RNA was eluted in a final volume of 50 lL and its optimal quality
checked.
2.1.4 HDL miRNA analysis by qPCR
Seven microlitres of RNA were reverse transcribed in 35lL reactions
using the miRCURY LNATM Universal RT microRNA PCR,
Polyadenylation and cDNA synthesis kit (Exiqon). cDNA was diluted
50 and assayed in 10mL PCR reactions according to the protocol for
miRCURY LNATM Universal RT microRNA PCR. A panel of 149
miRNAs homologous for pig and human were analysed in HDL
(Supplementary material online, Table S3). Each miRNA was assayed by
qPCR (microRNA Ready-to-Use PCR, Custom Pick and Mix panel using
ExiLENT SYBRVR Green master mix) and negative controls were run in
parallel. The amplification was performed in a LightCyclerVR 480 Real-
Time PCR System (Roche) in 384-well plates. The amplification curves
were analysed using the Roche LC software, both for Cq determination
(following the 2nd derivative method) and for melting curve analysis.
2.1.5 HDL miRNA data analyses
The amplification efficiency was calculated (LinReg software). All assays
were inspected for distinct melting curves and the Melt temperature
(Tm) was checked to be within known specifications for the assay.
Assays had to be detected beyond 5 Cqs of the negative control and
with Cq < 37 in order to be included in the data analyses. The
NormFinder helped to find out the best possible normalizer which
resulted to be the average of the best assays detected in all samples
(n = 20). The formula used to calculate the normalized Cq values was
the following: Normalized Cq = average Cq (n = 20) - assay Cq (sample).
We then performed a comparative analysis between NC and HC iso-
lated HDL-miRNAs. Data were expressed as fold-change.
2.2 Cell culture studies
2.2.1 Porcine aortic endothelial cells isolation, expansion
and treatment
Aortic ECs were obtained from regular-fed pigs by collagenase digestion
as previously described.24 Cells were cultured in growth M199 (Gibco)
medium supplemented with 10% FBS and antibiotics (0.1 mg/mL strepto-
mycin, 100 U/mL penicillin) until confluence. Cells were detached by
trypsin/EDTA treatment and seeded into larger flasks for expansion.



























































































Forty-eight hours after plating 300 000 cells in six well plates, 0.1% FBS
was added to the medium for 24 h and then EC were incubated with
NC-HDL (50mg/mL protein), HC-HDL (50mg/mL protein), or PBS/con-
trol for 18 h (in duplicates; n = 5) as previously reported.24,25 EC viability
was determined by trypan blue exclusion. ECs were always used be-
tween the third and seventh passage.
2.2.2 ECs and plasma miRNA isolation and data analysis
ECs were collected and total RNA was obtained with mirVANA miRNA
kit. The RNA was transcribed using TaqManVR Advanced miRNA cDNA
Synthesis Kit (Applied Biosystems; CA, EU) protocol. All assays were
performed in duplicates for the differentially expressed miRNAs includ-
ing miR-126-5p and -3p, let7g-5p, miR-103a-3p and miR-30b-5p (Life
Technologies; CA, EU) (n = 5). For normalization miR-423-3p and let-
7a-5p means were used as endogenous miRNA controls.26 The amplifi-
cation was performed in ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems; CA, EU) in 384-well plates. The amplifica-
tion curves were analysed using the Applied Biosystems Sequence
Detection System 2.4.1 software. Ct values were obtained and processed
by the standard curve method and normalized with the endogen. To ob-
tain fold difference vs. control the ratio sample/control was calculated.
Networks, functional analyses, detection of miRNAs targets and interac-
tions were generated by Ingenuity Pathway Analysis software (IPA) and
RNA hybrid tool.
2.2.3 Assessment of HDL-miRNA transfer to ECs
To investigate whether the scavenger receptor class B member 1 (SRB1)
was involved in HDL-miRNA transfer to ECs a specific SRB1 blocker,
BLT1 (EMD Millipore Corp, USA; 8mM), was added to ECs prior to
HDL incubation.25 In addition, and taking into consideration that miR-
126 (both 5p and 3p) is encoded in the 7th intron of the EGFL7 gene, we
assessed the expression of both EFGL7 and the pre-miRNA sequence
(pre-mir-126; n = 5) in ECs in order to ascertain whether the potential
intracellular changes detected in miR-126-5p and -3p expression were
related to an up-regulation of its cellular synthesis or because of transfer
from HDL. Pri-miR126 could not be investigated because there is no
commercial assay available for Sus scrofa so far.
2.3 miR126 target gene analysis
2.3.1 In silico analysis
Potential target genes were obtained by using databases TargetScan,
miRwalk (5UTR, CDS, 3UTR) and the Ingenuity Pathway Analysis (IPA;
http://www.ingenuity.com/), according to their search algorithms. The
functionality of target genes in cellular processes was predicted by IPA
Core analysis. Furthermore, RNAhybrid (Bielefeld University
Bioinformatics server) was used for calculating minimum free energy
(MFE), which indicates the accessibility of miRNAs at the target gene
binding sites. Target genes were selected by comparison of MFE
values.27
2.3.2 Gene expression validation
RNA was transcribed using the High Capacity cDNA Archive kit
(Applied Biosystems, Foster City, CA, USA) protocol for genomic RNA.
qPCRs were performed in duplicates for SCARB1, mir-126-5p and -3p,
HIF1a, vascular cell adhesion protein 1 (VCAM1), vascular endothelial
growth factor A (VEGFA) (Life Technologies; CA, EU), and EGFL7 (Bio-
Rad Laboratories, CA, EU). 18SrRNA was used as endogenous control
for tissue samples and GAPDH (Life Technologies; CA, EU) for EC
samples. The amplification was performed in ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems; CA, EU) in 384-well
plates. The amplification curves were analysed using the Applied
Biosystems Sequence Detection System 2.4.1 software. Ct values were
obtained and processed by the standard curve method and normalized
with the endogenous gene.
2.3.3 Protein expression validation
Cell lysis was performed according to the previous established proto-
col.28 The cell protein lysates were stored at -80C until use. Protein
concentrations were assessed using the BSA assay and then SDS–
polyacrylamide gel electrophoresis (SDS-PAGE) was run. Blots were
blocked with BSA at room temperature for 1 h and incubated with the
appropriate primary antibody [HIF1a (sc-10790, Santa Cruz
Biotechnology, Dallas, TX, USA)] at 4C overnight. Membranes were
then incubated with a horseradish peroxidase-conjugated anti-mouse
antibody for 2 h. Densitometry analyses were performed using commer-
cially available quantitative software (ImageLab Software, Bio-Rad
Laboratories, CA, USA) with the control representing 1.0-fold.
2.3.4 Mir126 target validation by miR126-mimic and
miR126 inhibitor
ECs were transfected with miR126-mimic or miR126 inhibitor (both for
-5p and -3p) (Life Technologies; CA, EU) with the LipofectamineTM
RNAiMAX Transfection Reagent (Life Technologies; CA, EU) following
the supplier recommendations. Then, ECs were treated with HDL-HC
or HDL-NC as reported above. A miRNA Mimic Negative Control #1
(Life Technologies; CA, EU) was run in parallel.
2.4 In vivo validation of miR-126 target
genes by confocal microscopy
We assessed HIF1a protein expression in the coronary arteries of nor-
mocholesterolaemic pigs (n = 12) administered HC-HDL (n = 6) or NC-
HDL (n = 6). In this regard, we processed the coronary arteries from
pigs of our previous published study19 which had been kept in our tissue
biobank at -80C until use. Accordingly, we fixed the proximal portion
of the coronary artery of all pigs in 4% paraformaldehyde and the
paraffin-embedded for confocal microscopy analysis. Serial sections
(5mm thick) were incubated with blocking buffer and then with antibody
against HIF1a (H1alpha67, Novus Biologicals, Littleton, CO, USA).
Preparations were counterstained with fluorescently labelled secondary
antibody (Invitrogen) and mounted with fluorescent medium.
Fluorescent images were acquired in a scan format of 1024 1024 pix-
els in a spatial data set (x y z). Controls with no primary antibody showed
no fluorescence labelling.
2.5 Statistics
The Shapiro–Wilk test was employed to analyse data normal or non-
normal distribution; data are reported as the mean ± standard deviation
and median (interquartile range), respectively. For the biochemical de-
scriptive data and SRB1 in vivo analysis, we performed non-parametric
test Kruskal–Wallis with Dunn’s multiple comparisons corrected test.
Tukey’s honest significance corrected test was used in conjunction with
an ANOVA (post hoc analysis) for multiple comparisons to find signifi-
cantly difference between group means due to its condition of indepen-
dent samples. Accordingly, t-test was used for two group independent
samples mean comparison. A two-sided P-value less than 0.05 was con-
sidered statistically significant.












































.Sample size: For the EC approach accepting a risk of 0.05 and b risk of
0.2 in a two-sided test, an n = 3 was necessary to recognize as statistically
significant difference >_0.5 units. Yet, we performed n = 5 in all conditions
to make our conclusions more robust. The common standard deviation
is assumed to be 0.2 and it we anticipated a dropout rate of 0%
(GRANMO software, Spain). All statistical analyses and graphics were per-
formed using GraphPad Prism 7.0 version software.
3. Results
3.1 HDL-characterization
Cholesterol content was two-fold higher in HC- than in NC-HDLs
(Supplementary material online, Table S4). This observation is in line
with our previous findings regarding the effects of hypercholesterolaemia
on modifying HDL-lipid composition.20 The isolated HDL samples were
free from ApoB (Supplementary material online, Figure S1A), Anexin Vþ
microvesicles (Supplementary material online, Figure S1B), and exosomes
(Supplementary material online, Figure S1C), supporting the purity of the
HDL preparations. The protein concentration was similar in HC-HDL
(5.7mg/mL) and in NC-HDL (5.6mg/mL).
3.2 HDL-related miRNA profile
Among the 149 miRNAs analysed, 30 miRNAs were detected in all HDL
samples (Figure 1 and Supplementary material online, Table S5). Among
these 30 miRNA, the amounts of five miRNAs were significantly different
in HC- and in NC-HDL particles (P < 0.05). Particularly, there was a
higher content of miR126-5p, miR126-3p, and miR-30b-5p in HC-HDL
particles as compared to NC-HDL (2.7, 1.7, and 1.3, respectively),
whereas, conversely, the amounts of miR103a-3p and let7g-5p were sig-
nificantly lower (-1.6, -1.4, respectively).
3.3 HC-HDL particles transfer miR-126 to
ECs through a SRB1-dependent
mechanism
ECs incubated with HC-HDL showed significantly higher intracellular
levels of miR-126-5p (P < 0.0001) and miR126-3p (P < 0.0001), while lev-
els of both miR-126s (5p and 3p) were similar in control ECs and ECs in-
cubated with NC-HDL (Figure 2A and B). No differences were observed
for miR103a-3p (Figure 2C), miR30b-5p (Figure 2D), and let7g-5p
(Figure 2E).
Interestingly, the internalization of miRNA-126 in ECs was mediated
by SRB1.We found that SRB1 blockade by BLT-1 abolished HC-HDL-
induced increase in miR-126 (both 5p and 3p) (Figure 3A and B) content.
SRB1 expression in ECs did not differ by incubation with either NC- or
HC-HDLs (Supplementary material online, Figure S2A). Moreover, com-
parable SRB1 transcript levels were detected in pig coronary arteries
and liver (Supplementary material online, Figure S2B). Therefore, SRB1
was found abundantly expressed in pig ECs and its expression was not
influenced by incubation with HDL. Finally, blockade of SRB1 in HDL-
and PBS-incubated cells led to comparable up-regulation in SRB1 levels
(Supplementary material online, Figure S3).
To further confirm the transfer of miR-126-5p and -3p from HC-HDL
to the ECs, we analysed pre-mir-126 and EGFL7 levels. As shown in
Figure 3, both pre-mir-126 (Figure 3C) and EGFL7 (Figure 3D) were simi-
larly expressed among all the three groups excluding an enhanced
Figure 1 HeatMap including the miRNAs detected in all HDL samples isolated from hypercholesterolaemic (HC; n = 10) and normocholesterolaemic
(NC; n = 10) pigs.



























intracellular transcription of miRNA-126 in HC-HDL-treated cells and
confirming transfer from HC-HDL.
3.4 miR-126 target genes on ECs
We used different computational databases (Supplementary material on-
line, Figure S4 and Table S6) to identify potential target genes of miR-126-
5p and -3p in ECs, and only those identified in at least two databases
were further investigated. We identified a total of 7597 candidate target
genes potentially regulated by miR-126 (3p-strands: 454; 5p-strands:
7143). Among them, common target genes were identified from at least
two databases (51 for miR-126-3p and 942 for miR-126-5p). HIF1a was
the potential best target gene for miR-126-5p regulation given the low
MFE values (-8.3, -11.2, -12.6, -12.1, -8.5, -13.1 Kcal/mol) and its six tenta-
tive binding sites for miR126-5p (Table 1). The best potential target for
miR126-3p was DR5 but it could not be validated because its sequence
is not yet available in S. Scrofa.
To further validate HIF1a as a target gene for miR126, we examined
the effects of miR-126-mimics and miR-126-inhibitors (both -5p and -3p)
in ECs (Figure 4). Indeed, control ECs transfected with both miR126-
mimics showed lower HIF1a transcript levels and protein expression
than ECs transfected with the negative control and both miR126-
inhibitors (Figure 4A–D and Supplementary material online, Figure S5).
HIF1a gene expression was lower in negative-control transfected ECs
incubated with HC-HDLs as compared to NC-HDL and control
(P < 0.05; Figure 4E and F and Supplementary material online, Figure S5).
In the EC cultures treated with HDL the effects of HL-HDL on the
down-regulation of HIF1a expression were abrogated by miR126-5p/3p
inhibitors (Supplementary material online, Figure S6).
Based on these findings, we proceeded to validate HIF1a by qPCR
(n = 5) and found that HIF1a transcript levels were significantly down-
regulated in ECs treated with HC-HDL (P < 0.01 vs. PBS/control;
P < 0.006 vs. NC-HDL; Figure 5A). HIF1a protein levels were also signifi-
cantly reduced in HC-HDL treated ECs (Figure5B).
Figure 2 Endothelial cells incubated with hypercholesterolaemic-HDL show higher miR-126-5p and 3p levels as compared to normocholesterolaemic-
HDL [miR126-5p (A) and miR126-3p (B)], whereas no differences were observed for 103a-3p (C), miR-30b-5p (D), or let-7g-5p (E) levels. n = 5. Data are
reported as mean ± SD. *ANOVA test P < 0.05 vs. Control and NC-HDL groups. HC: hypercholesterolaemic; NC: normocholesterolaemic.

































..Mimic-MiR126 (-5p and -3p) induced down-regulation of VCAM1
mRNA expression (Supplementary material online, Figure S7A and B)
and up-regulation of VEGFA mRNA expression (Supplementary mate-
rial online, Figure S7C and D).
3.5 In vivo validation of HC-HDL-related
miR-126 potential to modulate endothelial
HIF1a
Finally, to determine whether our in vitro findings translated into the
in vivo setting, we assessed HIF1a expression by confocal microscopy in
the coronary arteries of NC pigs administered HC- or NC- HDLs.
Interestingly, as shown in Figure 6, expression of HIF1a was markedly re-
duced in the intimal layer of the coronary arteries of those NC animals
administered HC-HDLs as compared to those administered NC-HDLs.
4. Discussion
In the present study, we report that: (i) HDL formed in hypercholestero-
laemic conditions transport different amounts of miRNAs than those
HDL formed in normocholesterolaemic conditions; (ii) miR-126-5p and
-3p content is higher in HC-HDL particles; (iii) HC-HDL transfer miR-
126 to ECs through a SRB1-dependent mechanism; (iv) internalized
miRNA-126 regulates HIF1a in recipient cells. HIF1a down-regulation is
observed in vivo as seen in the coronary arteries of animals treated with
HL-HDL but not in animals treated with NL-HDL.
During the last years, it has become increasingly evident that HDL can
transport multiple miRNAs including miR-12629, miR-10330, let-7g, miR-
222, and miR-2236 among others. However, it remained to be deter-
mined whether the presence of cardiovascular risk factors altered the
HDL transported miRNA signature. In the present study, we demon-
strate that HDL formed under hypercholesterolaemic conditions, be-
cause of high dietary fat intake, show a higher abundance of the miRNAs
miR-126-5p and -3p, and miR-30b-5p and, conversely, a lower amount
of miRNAs miR-103a-3p and let-7g-5p as compared to those HDL
formed in a normocholesterolaemic milieu. Interestingly, Vickers et al.6
had reported a differential HDL-miRNA signature (particularly miR223
levels) in familial hypercholesterolaemia patients that have high LDL-
cholesterol levels during life, due to the inherited condition of the dis-
ease. So far, a positive association between miR-126 levels in plasma and
in HDL has been described, as well as in coronary artery disease and
myocardial infarction.29,31,32 Furthermore, higher amount of miR-126
Figure 3 Hypercholesterolaemic HDL particles transfer miR-126-5p and -3p (A and B, respectively) to endothelial cells through a SRB1-dependent mech-
anism. No differences are detected for Pre-mir-126 (C) or for miR-126 encoding gene EGFL7 (D) levels among the different groups. n = 5. Data are reported
as mean ± SD. *ANOVA test P < 0.05 vs. any other group. HC: hypercholesterolaemic; NC: normocholesterolaemic.









..was found in HDL particles of overweight and obese subjects,33,34 and
we have recently shown that miR-126 regulates monocyte/macrophage
differentiation under a rich LDL-cholesterol environment.28 Indeed, a
positive association between miR-126 expression and LDL-cholesterol
levels has been demonstrated.35 Here, we demonstrate that HDL par-
ticles formed in a diet-induced hypercholesterolaemic milieu with high
LDL-cholesterol levels carry a high content of miR-126, which is deliv-
ered into ECs via a SRB1, leading to the down-regulation of its target
gene HIF-1a. As such, SRB1 blockade inhibited miR-126 (both -5p and -
3p) delivery into ECs pointing to the critical role of this receptor in
HDL-miRNA internalization into target recipient cells. This finding is fur-
ther supported by the fact that no changes are detected in pre-mir-126
Figure 4 Control ECs transfected with miR126-mimic show lower HIF1a gene levels as compared to ECs transfected with the negative control both at
mRNA expression and protein level (A–D). HIF1a-mRNA expression was lower in negative-control transfected ECs incubated with HC- as compared to
NC-HDLs and control (E and F). *ANOVA test P < 0.05. HC: hypercholesterolaemic; NC: normocholesterolaemic.































.(mir-126) or its encoding gene EGFL7.36 SRB1 is a membrane receptor
involved in the selective uptake of cholesteryl ester from HDL. SRB1 is
highly expressed in the liver and other cells including monocytes/
macrophages, ECs, smooth muscle cells, adipocytes, and steroidogenic
cells.37–39 The ability of HDL particles to transfer cargo-miRNAs into re-
cipient cells via SRB1 had already been described in macrophages and
hepatocytes.6 In fact, Vickers et al.6 reported that SRB1 over expression
associated with the greatest cellular uptake of HDL-miRNAs.
Whereas in rodents SRB1 is expressed most abundantly in tissues
that efficiently utilize cholesterol ester (biliary cholesterol secretion or
steroid hormone production),40 in humans SRB1 is homogenously dis-
tributed in all cells.41 In the present study, we show that in pigs there are
comparable SRB1 expression levels in the liver and arterial beds. It is
possible that SRB1 serves as docking receptor for HDL to transfer their
miRNA-cargo into target cells. Although the SRB1 is the endothelial re-
ceptor mainly involved in HDL-miRNA transfer, we cannot exclude that
other HDL receptors (ABCA1, ABCG1) may also be involved in HDL-
miR126 transfer to ECs.42
The role of miR-126 on the cardiovascular system is controversial,
with opposed results in different studies. miR-126 has shown to regulate
angiogenesis and blood vessel integrity by directly repressing the
Sprouty Related EVH1 Domain Containing 1 (SPRED1)43 gene and the
phosphoinositide-3-kinase regulatory subunit 244,45 with the consequent
increase in VEGFA.46 Moreover, miR-126 has also shown to reduce
leucocyte adherence and vascular inflammation by targeting VCAM-1.47
On the other hand, LDL-cholesterol and miRNA-126 levels are posi-
tively associated in patients with asymptomatic coronary artery disease
and have been suggested to exert prognostic value for future cardiovas-
cular events.48 In line with previous work, we further confirm the ability
of miR-126 to down-regulate endothelial VCAM-1 expression and indi-
rectly enhance VEGFA transcript levels; yet, we further demonstrate the
ability of both miR-126s’ (5p and 3p) to reduce endothelial HIF1a gene
levels. Moreover, our in vitro findings are further recapitulated in vivo
where HIF1a protein levels are lower in the intima of the coronary ar-
teries of hypercholesterolaemic pigs. Although the complexity of the
in vivo model does not allow to exclude the existence of other potential
mechanisms modulating HIF-1a, all animals were kept under identical
conditions except for the type of infused HDL. It is, therefore, plausible
to consider that the changes observed in endothelial HIF1a may derive
from HC-HDL-miR126 transfer. HIF1a is a transcription factor that
Figure 5 mRNA expression and protein levels of miR126 target HIF1a in endothelial cells. n = 5. Data are reported as mean ± SD. *ANOVA test
P < 0.05 vs. Control and NC-HDL groups. HC: hypercholesterolaemic; NC: normocholesterolaemic.

































serves as a hypoxia sensor to induce the expression of angiogenic genes.
Yet, under normoxic conditions, HIF1a is known to modulate compen-
satory and adaptive mechanisms. In this regard, Liu et al.49 have recently
described in cancer cells that suppression of miR-126 increases HIF1a
expression promoting metastasis and therapeutic resistance. We evi-
dence, in ECs, that overexpression of miR-126 reduces HIF1a expres-
sion likely interfering with metabolic adaptation, innate immune
response, survival and apoptosis.50 On the other hand, HIF1a has been
described to be modulated, under hypoxic conditions, by miR-155,51
miR-18a, miR-199a, miR-429, miR-433,52 and miR-497195.53,54 The
exact mechanism by which HDL are loaded with miR-126 under hyper-
cholesterolaemic condition is not known. Biophysical studies have sug-
gested that dipolar lipids facilitate small RNAs incorporation within HDL
particles.55 In this regard, we could speculate that the reported changes
in lipid composition observed in HC-HDL particles20 may have favoured
miR-126 association to circulating HDLs. Yet, further studies are needed
to confirm this hypothesis and determine the relevance of modulating
miR-126 expression in the vascular wall. In this regard, the in vivo func-
tional impact of miR-126/HIF1a deserves to be investigated.
In conclusion, we demonstrate that diet-induced hypercholesterolae-
mia leads to alterations in HDL-miRNA profile favouring an enrichment
in miR-126 that can be delivered to ECs interfering with key vascular
functions. Collectively, our data provides further insights as to the impact
of hypercholesterolaemia on HDL biogenesis, HDL biology, and HDL
composition as well as on the potential outcomes on HDL-miRNA
intercellular communication. Whether miR-126 may serve as a potential
therapeutic target or whereas reversing hypercholesterolaemia (statin
treatment, diet approaches) may restore HDL-related miRNA normal
profile deserve to be investigated.
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Translational perspectives
Clinical trials aimed at increasing high-density lipoprotein (HDL)-cholesterol in secondary prevention have resulted disappointing. Furthermore, stud-
ies have reported on the negative impact of cardiovascular disease on HDL composition and function. The structural/functional changes that suffer
HDL particles under cardiovascular comorbid pathological conditions need to be investigated because they render them dysfunctional and even dele-
terious. We evidence that diet-induced hypercholesterolaemia (the most prevalent cardiovascular risk factor) alters HDL miRNA signature and these
altered miRNAs directly affect vascular homeostasis, adversely regulating the vascular response. Identifying the remodelling changes affecting HDL
particles due to pathological conditions will open new avenues for therapeutic intervention.
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